Navigation Links
Owing to Generic Erosion of Key Agents, the Colorectal Cancer Drug Market Will Remain Relatively Flat Through 2019

BURLINGTON, Mass., Sept. 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, owing to generic erosion of key agents, the colorectal cancer drug market will remain relatively flat over the next decade, increasing from more than $6.4 billion in 2009 to just under $6.7 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

The Pharmacor 2010 findings from the topic entitled Colorectal Cancer reveal that the market leader -- Genentech/Roche/Chugai's Avastin -- will be minimally challenged in the colorectal cancer drug market over the next decade. Despite the emergence of biosimilar versions of Avastin, which is expected to begin in 2018, and increasing first-line use of other targeted agents, Avastin sales will decline only slightly from just over $2 billion in 2009 to $1.86 billion in 2019. Additionally, the entry of two new vascular endothelial growth factor (VEGF)-targeted agents into the market, Regeneron/Sanofi-Aventis's aflibercept (VEGF Trap) and ImClone Systems/Eli Lilly's ramucirumab, will fail to make a significant impact, together garnering only 4.9% of major market sales.

The Pharmacor 2010 findings also reveal that Bristol-Myers Squibb/ImClone Systems/Merck Serono's Erbitux dominates the epidermal growth factor receptor (EGFR) inhibitors class, mainly because it was first drug in its class to launch for the indication, it can be used in combination with chemotherapy and has been approved in Europe and Japan for use in the lucrative first-line setting.

"Through 2019, Erbitux's market share will grow incrementally, even in the face of biogeneric erosion and the use of additional anti-EGFR treatments in the first- and second-line settings," said Decision Resources Analyst Regina Jammen. "Erbitux's first-to-market position has helped establish it as the market-leading anti-EGFR therapy."

The findings also reveal that, although a variety of suitable treatments for the indication are available, new therapies are required that will meet the needs of subsets of colorectal cancer patients. Several treatments that are expected to launch by 2019 will meet some of the needs of heavily pretreated patients with KRAS (Kirsten rat sarcoma viral oncogene homologue) mutations, patients with liver metastases and high-risk stage II patients. These late-stage therapies include AEterna Zentaris/Keryx Biopharmaceuticals' perifosine (KRX-0401), Light Sciences Oncology/Nippon Petrochemicals/Meiji Seika Kaisha's Aptocine/Laserphyrin (talaporfin) and the OncoVax vaccine, Vaccinogen.

"However, we forecast that none of these late-stage therapies will achieve blockbuster sales for colorectal cancer," Ms. Jammen said.

About Pharmacor 2010The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision ResourcesDecision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision Resources, Inc.Christopher Comfort781-993-2597

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
2. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
3. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
4. Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery
5. Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery
6. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
7. Human Genome Sciences Presents New Data Showing Anti-Tumor Activity And Safety Of Trail Receptor Antibodies In Combination With Chemotherapy
8. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
9. IDM Pharma Announces Updated Phase 2 UVIDEM(R) Results Showing Durable Disease Control and Tolerability in Advanced Melanoma Patients
10. VIA Pharmaceuticals Presents Data at American Heart Association Meeting Showing VIA-2291 Significantly Reduces Inflammation in Preclinical Model of Atherosclerosis
11. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
Post Your Comments:
(Date:10/7/2017)... --  Provista, a proven leader in the supply ... power, today announced a new resource area on ... is the online home for case studies, articles on ... releases, slideshows and events. ... at their fingertips, viewers can also watch short videos ...
(Date:10/4/2017)... , Oct. 4, 2017 ... single-use, self-contained, illuminating medical devices, today announced regulatory ... Health Surveillance Agency (or Agência Nacional de Vigilância ... first single-use, cordless surgical retractor with integrated LED ... optimal access, illumination and exposure of a tissue ...
(Date:10/2/2017)... announces the European launch of their new low volume, high throughput ... Cambridge, U.K on October 4th. The new ... unprecedented speed and sensitivity while using far less sample volume through ... ... ...
Breaking Medicine Technology:
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris F. ... AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking place ... the field of medical informatics, this prestigious award is presented to an individual whose ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare ... Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during ... , The annual award competition recognizes editorial and design excellence across a range of ...
(Date:10/12/2017)... ... 12, 2017 , ... On Saturday, October 21, the Health & Wellness Center ... to raise money for the American Heart Association Heart Walk. Teams of up to ... together to keep their treadmills moving for 5 hours. Treadmills will start at 7:00 ...
Breaking Medicine News(10 mins):